# HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma

> **NCT05290220** · PHASE2 · UNKNOWN · sponsor: **Shanghai Henlius Biotech** · enrollment: 60 (estimated)

## Conditions studied

- Advanced Hepatocellular Carcinoma

## Interventions

- **DRUG:** HLX07
- **DRUG:** HLX10
- **DRUG:** HLX04
- **DRUG:** lenvatinib

## Key facts

- **NCT ID:** NCT05290220
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-01
- **Primary completion:** 2023-12-15
- **Final completion:** 2024-12-15
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05290220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05290220, "HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05290220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*